ICO Share Price

Open 0.04 Change Price %
High 0.04 1 Day 0.00 0.00
Low 0.04 1 Week 0.00 0.00
Close 0.04 1 Month 0.00 0.00
Volume 10000 1 Year 0.00 0.00
52 Week High 0.09
52 Week Low 0.03
ICO Important Levels
Resistance 2 0.04
Resistance 1 0.04
Pivot 0.04
Support 1 0.04
Support 2 0.04
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PHM 0.40 -4.76%
PHM 0.40 -4.76%
PHM 0.40 -4.76%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
More..
CVE Canada Top Gainers Stocks
BVQ 0.02 100.00%
BGS 0.02 100.00%
BGS 0.02 100.00%
DDX 0.50 100.00%
AZU 0.02 100.00%
AZU 0.02 100.00%
RDM 0.21 90.91%
RDM 0.21 90.91%
SHM 0.24 71.43%
SHM 0.24 71.43%
More..
CVE Canada Top Losers Stocks
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
GB 0.10 -41.18%
GB 0.10 -41.18%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
More..

ICO Therapeutics Inc (CVE: ICO)

ICO Technical Analysis 4
As on 24th May 2017 ICO Share Price closed @ 0.04 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.05 & Strong Sell for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
ICO Target for May
1st Target up-side 0.06
2nd Target up-side 0.06
3rd Target up-side 0.06
1st Target down-side 0.04
2nd Target down-side 0.04
3rd Target down-side 0.04
ICO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.icotherapeutics.com
ICO Address
ICO
760-777 Hornby Street
Vancouver, BC V6Z 1S4
Canada
Phone: 604-602-9414
Fax: 604-602-9699
Interactive Technical Analysis Chart ICO Therapeutics Inc ( ICO CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ICO Therapeutics Inc
ICO Business Profile
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-007, an antisense inhibitor that is in Phase II clinical trial for the treatment of diabetic macular edema; and iCo-008 (Bertilimumab), a human immunoglobulin monoclonal antibody, which is in Phase I clinical trial to treat sight threatening ocular allergies and various systemic indications. The company also develops Oral Amphotericin B Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections in immune-compromised patients, such as in HIV/AIDS, cancer, transplant recipients, diabetics, etc., as well as certain parasitical infections. iCo Therapeutics Inc. has partnership arrangements with Isis Pharmaceuticals, Inc.; MedImmune Limited; Immune Pharmaceuticals Inc.; AstraZeneca; and the University of British Columbia. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.